3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Ovarian Neoplasms
3
Mesothelioma, Malignant
3
Solid Tumors
2
Neoplasm Metastasis
2
Disease Progression
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Parathyroid Neoplasms
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Medullary
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumors
1
Adenocarcinoma, Follicular
1
Interventions
Carboplatin
49
Etoposide
46
Cisplatin
42
Topotecan
39
Irinotecan
21
Paclitaxel
20
Nivolumab
15
pembrolizumab
13
Gemcitabine
13
atezolizumab
11
Ipilimumab
11
durvalumab
9
Radiotherapy
9
Doxorubicin
7
Bevacizumab
7
rovalpituzumab tesirine
6
etoposide phosphate
6
amrubicin
6
Psychiatric Rehabilitation
6
PM 01183
6
Docetaxel
6
Counseling
6
trilaciclib
5
Temozolomide
5
Sunitinib
5
Platinum
5
Imatinib Mesylate
5
Cyclophosphamide
5
Bortezomib
5
130-nm albumin-bound paclitaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Small Cell Lung Carcinoma
×
tumor necrosis factor-alpha, CNGRC fusion protein, human
×
Clear all
NCT00483509
2019-10-04
NGR007
AGC Biologics S.p.A.
Phase 2
Completed
28 enrolled
10 charts